The following is a summary of “Impact of Race on Sacubitril/Valsartan use of HF,” published in the October 2024 issue of Cardiology by Lu et al. There is limited understanding of how self-reported ...
In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...
The PARADIGM-HF and PARAGON-HF trials demonstrated consistent benefits of sacubitril/valsartan relative to RAS inhibitors in ...
You may qualify for a study at the University of Alabama at Birmingham exploring the effects of sacubitril/valsartan on your ...
Sacubitril/valsartan may be a better treatment option compared with ACEi/ARBs for patients with malignant hypertension-associated thrombotic microangiopathy. Kidney recovery is better when thrombotic ...
A federal judge rejected Novartis Pharmaceuticals Corp.’s motion to declare as unlawful the FDA’s approval of a rival version of its heart failure drug Entresto. In the sealed memorandum, the judge ...
Sacubitril/valsartan significantly reduces NT-proBNP levels in patients with heart failure with reduced ejection fraction (HFrEF) over 3 years, with no significant changes in sST2 and galectin-3.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback